This has been observed in non-small cell lung cancer (NSCLC) for EGFR targeting drugs, where 50% of patients treated with erlotinib and gefitinib develop a threonine-to-methionine mutation (T790M) within one year. Here, EGFR is linked to non-small cell lung carcinoma.